Kyowa Kirin Co., Ltd.

4151.T
Drug Manufacturers - Specialty & Generic
2026/03/13 Updated
Market Cap: $7.6B (¥1.2T)
Stock Price: $14.51 (¥2,303)
Exchange Rate: 1 USD = ¥158.73

(Correction: Numerical Data Correction) Partial Correction Regarding the “Financial Summary for the Fiscal Year Ending December 2025 [IFRS] (Consolidated)”

Corrected an error in the calculation of “Payments for acquisition of property, plant and equipment” in the consolidated cash flow statement of the financial summary for the fiscal year ending December 2025, revising cash flows from operating activities from JPY 100,016 million to JPY 96,619 million.

Importance:
Page Updated: March 9, 2026
IR Disclosure Date: March 9, 2026

Key Figures

  • Cash Flows from Operating Activities: JPY 96,619 million (before correction JPY 100,016 million)
  • Cash Flows from Investing Activities: △JPY 89,189 million (before correction △JPY 92,586 million)
  • Cash and Cash Equivalents at End of Period: JPY 218,769 million (unchanged)

AI要約

Overview of Correction

In the "Financial Summary for the Fiscal Year Ending December 2025 [IFRS] (Consolidated)" announced on February 9, 2026, an error was found in the calculation process of "Payments for acquisition of property, plant and equipment" in the consolidated cash flow statement. Consequently, the figures for cash flows from operating activities and investing activities were corrected. Cash flows from operating activities were revised from JPY 100,016 million to JPY 96,619 million, and cash flows from investing activities were revised from △JPY 92,586 million to △JPY 89,189 million. Other figures for cash flows from financing activities and the balance of cash and cash equivalents at period-end remain unchanged.

Impact of Correction and Future Response

This correction is limited to adjustments to certain figures in the cash flow statement, with no fundamental changes to business performance or outlook. It aims to provide investors with accurate financial information, and the company will continue to strive for accuracy in disclosures going forward.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.